The changing global epidemiology of Acinetobacter baumannii infections: a development with major public health implications  by Falagas, M.E. & Karveli, E.A.
EDITORIAL 10.1111/j.1469-0691.2006.01596.x
The changing global epidemiology of Acinetobacter baumannii infections:
a development with major public health implications
M. E. Falagas1,2,3 and E. A. Karveli1
1Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece, 2Department of Medicine, Tufts
University School of Medicine, Boston, MA, USA and 3Department of Medicine, Henry Dunant
Hospital, Athens, Greece
ABSTRACT
Acinetobacter baumannii infections have become increasingly common among critically-ill patients in
intensive care units (ICUs) worldwide. A. baumannii clinical isolates are frequently resistant to most
antimicrobial agents and evidence of pan-drug resistance among A. baumannii isolates (i.e., resistance to
all available antimicrobial agents, including polymyxins) has been reported. These facts constitute an
alarming development in the ﬁeld of infectious diseases, with major public health implications. More
intensive efforts are urgently required to elucidate the epidemiological and infection control issues
related to these organisms and to improve the management of patients with such infections.
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Recent years have witnessed signiﬁcant changes
in the global epidemiology of infections caused by
Acinetobacter spp. Members of this genus have
been recognised as rare human pathogens since
the 1970s, but recent decades have seen an
increasing number of reports concerning infec-
tions of patients with Acinetobacter, particularly in
the intensive care unit (ICU) setting, which have
been attributed mainly to Acinetobacter baumannii
[1]. The increasing body of literature on this
subject suggests that Acinetobacter infections occur
mainly in four patient populations and settings:
(i) infections acquired by patients in ICUs;
(ii) healthcare-associated infections acquired out-
side the ICU setting; (iii) infections in trauma
patients, often following natural disasters, such as
earthquakes, or outbreaks of war, and (iv) com-
munity-acquired infections, mainly pneumonia,
but also bacteraemia, cellulitis and meningitis,
which usually affect patients with co-morbidities
in tropical and sub-tropical areas.
Most healthcare-associated Acinetobacter infec-
tions have occurred in critically-ill patients
receiving care in the ICU setting [2]. A number
of reports from various parts of the world have
suggested that the incidence of A. baumannii
infections in ICU patients is increasing [3–6],
and a recent review of the literature suggests that
a higher proportion of ICU patients in European
and Asian hospitals develop nosocomial infection
caused by A. baumannii than occurs in USA
hospitals. In addition, the antimicrobial resistance
pattern is more extensive for A. baumannii isolates
from patients in Asian and European ICUs than
from patients in USA ICUs (personal unpublished
data).
A. baumannii is isolated frequently from the
tracheobronchial secretions of mechanically-ven-
tilated patients [7]. A signiﬁcant proportion of
these patients are simply colonised, whereas the
rest develop clinically signiﬁcant infection of the
respiratory tract. There is controversy among
various investigators and clinicians as to whether
A. baumannii infection in critically-ill patients in
the ICU setting is associated with a directly
attributable increase in mortality. However, a
systematic review of matched case-control and
cohort studies that evaluated the attributable
mortality of A. baumannii infections, although
not conclusive, strongly suggested that A. bau-
mannii infections are indeed associated directly
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with attributable mortality [8]. In addition, an
analysis of the available data from patients with
A. baumannii infections in our own hospital indi-
cated that appropriate empirical treatment of such
infections was associated with improved survival
rates [9].
During the last few years, increasing numbers
of patients who have acquired nosocomial
Acinetobacter infections outside the ICU setting
have been reported. Most of these patients have
respiratory tract infections, but a minority of
patients have bacteraemia with an unknown
primary site [10,11]. This is an alarming devel-
opment as it demonstrates the potential for this
pathogen to become a major cause of health-
care-associated infections outside the ICU set-
ting, thus signiﬁcantly expanding the patient
population at risk.
Clinical and microbiological data and experi-
ence acquired from the care of casualties of the
earthquake in Marmara, Turkey (1999) [12], as
well as those of the recent wars in Kuwait, Iraq
and Afghanistan, have demonstrated convin-
cingly that a signiﬁcant proportion of trauma
casualties, at least in these areas of the world, are
at risk of infections caused by Acinetobacter spp.
[13]. A considerable proportion of such patients
suffered wound infections caused byAcinetobacter,
mainly in the extremities, as well as osteomyelitis.
It is also worth mentioning that, in some cases,
epidemics of nosocomial Acinetobacter infections
occurred (usually bacteraemia and ⁄ or pneu-
monia) in European and American hospitals in
which soldiers with Acinetobacter infections re-
ceived care after their initial management in ﬁeld
hospitals.
There have also been several reports of com-
munity-acquired infections involving various
Acinetobacter spp., including A. baumannii, mainly
in patients with some type of co-morbidity, e.g.,
diabetes mellitus, alcohol abuse or chronic
obstructive pulmonary disease [14]. Most of these
reports originate from tropical or sub-tropical
areas. It has also been suggested that the humid
environment of these areas predisposes individ-
uals, especially those with the above mentioned
co-morbidities, to Acinetobacter infections [15]. The
ongoing modiﬁcations of the global climate that
have occurred over the last decades as a result of
various human interventions (i.e., global warm-
ing) may cause changes in the epidemiology of
community-acquired Acinetobacter infections,
making them more frequent occurrences in other
areas of the world.
Numerous reports worldwide have documen-
ted increasing antimicrobial resistance among
A. baumannii clinical isolates. It seems that the
pattern of antimicrobial resistance is more exten-
sive in isolates from patients who receive ICU
care in certain European, Asian and South Ameri-
can hospitals [16–18]. Less extensive antimicrobial
resistance patterns have been reported for A. bau-
mannii isolates from patients in ICUs in the USA,
The Netherlands and the Nordic countries [19].
Among these reports, those that describe pan-
drug resistance (i.e., resistance to all available
antimicrobial agents, including polymyxins) have
obvious clinical signiﬁcance and tremendous
public health implications [20].
In conclusion, the available evidence suggests
that A. baumannii is an important human patho-
gen that is gradually gaining more attention as a
public health threat. It causes a signiﬁcant pro-
portion of infections in speciﬁc patient popula-
tions, especially in critically-ill patients receiving
care in the ICU setting. This situation, together
with the fact that A. baumannii isolates have
inherent and ⁄ or easily acquired mechanisms of
resistance against many of the available antimi-
crobial agents, makes this pathogen one of the
most signiﬁcant microbial challenges of the cur-
rent era. More scientiﬁc efforts and resources are
urgently needed to further elucidate the epide-
miological and infection control issues related to
A. baumannii infections, and to investigate treat-
ment options for patients with multidrug- or pan-
drug-resistant infections.
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